Program
Aticaprant
Also written as “JNJ-67953964”, “14C-aticaprant” and “Aticaprant Supratherapeutic Dose”.
Its studies are mostly in Depressive Disorder, Major · Schizophrenia · Smoking · Alcoholism, led by 2 companies.
Drug pageAticaprant: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 121 open or running | phase 3since Jul 10, 2022 | Dec 15, 2015 | Jun 21, 2027phase 1 · NCT07615426 |
| Eli Lilly | 10 open or running | phase 1since Oct 20, 2010 | Oct 20, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 20, 2010First study: phase 1 study in AlcoholismFirst studyNCT01232439 · 13 enrolled · United States
- Jun 9, 2018Named aticaprantINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JNJ-67953964
TargetBeta
“Kappa opioid receptor antagonist”ChEMBL 37, by rule
Other programs on OPRK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 21 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| nalfurafinerule | toray-industries-inc | phase 3 | 9 |
| asimadolinerule | tioga-pharmaceuticals | phase 3 | 6 |
| icalcaprant | AbbVie | phase 2 | 6 |
Studies
The one study Eli Lilly leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01232439Alcoholism · United States | 1 | Completed | Apr 2011 | 13 |
How it is read
Names in the registry
- “Aticaprant”, 6 entries
- “JNJ-67953964”, 3 entries
- “14C-aticaprant”, 1 entry
- “Aticaprant Supratherapeutic Dose”, 1 entry
- “Aticaprant Therapeutic Dose”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 6 studies
- Schizophrenia, 1 study
- Smoking, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.